PT - JOURNAL ARTICLE AU - Gupta, Himanshu AU - Rubio, Mercedes AU - Sitoe, Antonio AU - Varo, Rosauro AU - Cisteró, Pau AU - Madrid, Lola AU - Cuamba, Inocencia AU - Jimenez, Alfons AU - Martiáñez-Vendrell, Xavier AU - Barrios, Diana AU - Pantano, Lorena AU - Brimacombe, Allison AU - Bustamante, Mariona AU - Bassat, Quique AU - Mayor, Alfredo TI - Plasma microRNA profiling for malaria disease: association with severity and <em>P. falciparum</em> biomass AID - 10.1101/2020.07.31.20165712 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.31.20165712 4099 - http://medrxiv.org/content/early/2020/08/04/2020.07.31.20165712.short 4100 - http://medrxiv.org/content/early/2020/08/04/2020.07.31.20165712.full AB - Severe malaria (SM) is a major public health problem in malaria-endemic countries. Sequestration of Plasmodium falciparum (Pf) infected erythrocytes in vital organs and the associated inflammation leads to organ dysfunction. MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of SM. This study applied next-generation sequencing to evaluate the differential expression of miRNAs in SM compared to uncomplicated malaria (UM). Six miRNAs were associated with in vitro Pf cytoadhesion, severity in Mozambican children and Pf biomass. Relative expression of hsa-miR-4497 quantified by TaqMan-RT-qPCR, was higher in SM children plasmas compared to that of UM (p&lt;0.048), and again correlated with Pf biomass (p=0.033). These findings suggest that different physiopathological processes in SM and UM lead to differential expression of miRNAs and pave the way to future studies aiming to assess the prognostic value of these miRNAs in malaria.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Instituto de Salud Carlos III (PI13/01478 cofunded by the Fondo Europeo de Desarrollo Regional [FEDER], CES10/021-I3SNS to AM and CP11/00269 from the Miguel Servet program to QB). HG was supported (Jan/2017-Jan/2019) by the Science and Engineering Research Board (SERB), Department of Science &amp; Technology, Government of India (SB/OS/PDF-043/2015-16, Overseas Postdoctoral Fellowship). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya (http://cerca.cat/en/suma/). CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). This research is part of ISGlobals Program on the Molecular Mechanisms of Malaria, which is partially supported by the Fundacion Ramon Areces.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols for each of the two case-control studies from which this analysis was derived were approved by the National Mozambican Ethical Review Committee (Mozambique) and Hospital Clinic (Barcelona, Spain).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed in this study are available from the corresponding author on request.